Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

February 25, 2025 Sandoz family foundation offers $3 billion worth of Novartis shares Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares ...

A doctor holding a microscope in front of a laboratory sample of healthcare products. Forward P/E Ratio: 10.27 Earnings Growth This Year: 7.93% Number of Hedge Fund Holders: 33 Novartis AG (NYSE ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...

Connor Clark & Lunn Investment Management Ltd. lowered its position in Novartis AG (NYSE:NVS – Free Report) by 95.6% in the 4th quarter, according to the company in its most recent Form 13F filing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.